Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
Phase II trial of oral study drug in patients with advanced metastatic breast cancer who have experienced failure of an anthracycline, a taxane, and capecitabine Clinical Trials Info presented on Clinical Trials Search is not intended to be a substitute for certified medical advice, visits or professional assistance using a real physician. We are not physicians. Always consult your dr. about Phase II trial of oral study drug in patients with advanced metastatic breast cancer who have experienced failure of an anthracycline, a taxane, and capecitabine conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Phase II trial of oral study drug in patients with advanced metastatic breast cancer who have experienced failure of an anthracycline, a taxane, and capecitabine Clinical research trials and Phase II trial of oral study drug in patients with advanced metastatic breast cancer who have experienced failure of an anthracycline, a taxane, and capecitabine health trials happen in many of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new drugs. The function of the studies / projects is to resolve particular human medical questions. Clinical trials are a popular manner for mDs, government agencies, and private sector corporations to discover remedies for all varieties of circumstances, like Phase II trial of oral study drug in patients with advanced metastatic breast cancer who have experienced failure of an anthracycline, a taxane, and capecitabine. Phase II trial of oral study drug in patients with advanced metastatic breast cancer who have experienced failure of an anthracycline, a taxane, and capecitabine Clinical Trials and other clinical trials allow volunteers to obtain healthcare treatment options before they are available to the masses. Some times the participants undergo professional assistance for free of charge, and occasionally they are paid for their time. Sometimes there is a cost for a Phase II trial of oral study drug in patients with advanced metastatic breast cancer who have experienced failure of an anthracycline, a taxane, and capecitabine clinical trial. Human subjects often get the best healthcare available for their Phase II trial of oral study drug in patients with advanced metastatic breast cancer who have experienced failure of an anthracycline, a taxane, and capecitabine condition. Dangers are a reality, however, and may include additional or frequent mD visits, healthcare dangers (potentially life-jeopardising), and/or the treatment being ineffectual. Trials are federally governed with rigorous guidelines to protect clinical trials patients.

Home > "P" Clinical Trials Conditions > Phase II trial of oral study drug in patients with advanced metastatic breast cancer who have experienced failure of an anthracycline, a taxane, and capecitabine

Phase II trial of oral study drug in patients with advanced metastatic breast cancer who have experienced failure of an anthracycline, a taxane, and capecitabine



Phase II trial of oral study drug in patients with advanced metastatic breast cancer who have experienced failure of an anthracycline, a taxane, and capecitabine

For Condition: Neoplasm Metastasis,Breast Cancer
Status: Recruiting
Sponsor(s): Pfizer ,
Synopsis: Phase II randomized, open-label study of 2 schedules of single-agent oral study drug in women with metastatic breast cancer who have experienced failure of prior therapy with an antrhacycline, a taxane, and capecitabine. Patients will receive oral study drug capsules either once each day for 5 days, or once a day for 14 days in 3 week cycles.
Details:
Eligibility:
Study Type:
  Interventional, Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: - Women with diagnosis of primary adenocarcinoma of the breast - Presence of locally advanced or metastatic disease non-amenable to surgery or radiation therapy with curative intent - At least one measurable lesion >20mm (or >10 mm with spiral CT scan) - Must have received (and failed) prior treatment with an anthracycline, a taxane, and capecitabine in the adjuvant and/or advanced disease treatment setting - Women at least 18 years old, with performance status 0-2
Total Enrollment: 170

Location and Contact Information:

Pfizer Investigational Site *Not yet recruiting*
Jacksonville,  Florida,  32224
United States
Not yet recruiting  

Pfizer Investigational Site *Recruiting*
Capital Federal,  Buenos Aires,  1426
Argentina
Recruiting  

Pfizer Investigational Site *Recruiting*
Nashville,  Tennessee,  37205
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
South Brisbane,  Queensland,  4101
Australia
Recruiting  

Pfizer Investigational Site *Recruiting*
Nashville,  Tennessee,  37203
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Lakewood,  Washington,  98499
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Nashville,  Tennessee,  37211
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Nashville,  Tennessee,  37203
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Franklin,  Tennessee,  37067
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Chalmette,  Louisiana,  70043
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Tyler,  Texas,  75702
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Rosario,  Santa Fe,  2000
Argentina
Recruiting  

Pfizer Investigational Site *Recruiting*
Seattle,  Washington,  98195
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Gallatin,  Tennessee,  37066
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Dallas,  Texas,  75204
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Santa Fe,  ,  3000
Argentina
Recruiting  

Pfizer Investigational Site *Recruiting*
Seattle,  Washington,  98104
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Mandeville,  Louisiana,  70448
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
New York City,  New York,  10021
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Cordoba,  ,  5000
Argentina
Recruiting  

Pfizer Investigational Site *Recruiting*
Nashville,  Tennessee,  37205
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Boston,  Massachusetts,  02115
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Seattle,  Washington,  98122
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Capital Federal,  Buenos Aires,  1406
Argentina
Recruiting  

Pfizer Investigational Site *Recruiting*
New Orleans,  Louisiana,  70115
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Metairie,  Louisiana,  70006
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Nashville,  Tennessee,  37207
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Covington,  Louisiana,  70433
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
New York City,  New York,  10021
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Federal Way,  Washington,  98003
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Nashville,  Tennessee,  37205
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Frankston,  Victoria,  3199
Australia
Recruiting  

Pfizer Investigational Site *Recruiting*
Bogota,  Bogota DC,  464
Colombia
Recruiting  

Pfizer Investigational Site *Recruiting*
Lebanon,  Tennessee,  37087
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Murfreesboro,  Tennessee,  37130
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Nashville,  Tennessee,  37205
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Seattle,  Washington,  98104
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Boston,  Massachusetts,  02114
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
New Orleans,  Louisiana,  70115
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Stony Brook,  New York,  11794
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Seattle,  Washington,  98109
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Tacoma,  Washington,  98405
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Metairie,  Louisiana,  70006
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Nashville,  Tennessee,  37203
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Nashville,  Tennessee,  37203
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Metairie,  Louisiana,  70002
United States
Recruiting  

Pfizer Investigational Site *Recruiting*
Hermitage,  Tennessee,  37076
United States
Recruiting  


Additional Information:
Study ID Numbers:
  CPTAPO-0047-146; 
Study Start Date: November 2003
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00072852

Other Neoplasm Metastasis Studies:
1. Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease

2. Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer

3. Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain

4. A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy with G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients

5. Primary Chemotherapy with Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer

Related Studies:

Other Neoplasm Metastasis Clinical Trials
Other Washington Clinical Trials
Other Lakewood Clinical Trials

Phase II trial of oral study drug in patients with advanced metastatic breast cancer who have experienced failure of an anthracycline, a taxane, and capecitabine

Modify your Search

  Other Neoplasm Metastasis Clinical Trials
  Other Washington Clinical Trials
  Other Lakewood Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103